Le Lézard
Classified in: Health, Business
Subject: ERN

Getinge Q3 2019 Result: Continued Growth and Improved Margins


GOTHENBURG, Sweden, Oct. 18, 2019 /PRNewswire/ -- "We continue to show strong organic sales growth and improved margins in the third quarter", says Mattias Perjos, President & CEO at Getinge. "The underlying cash flow remains strong despite that we seasonally are tying up more capital in the third quarter. In the coming quarters we will continue creating value for our customers and to work on strengthening profitability".  

Getinge's organic sales growth is continuing across all business areas and regions. The organic order intake amounted to 3.5%, despite tough comparative figures following a long period of outperforming market growth. Getinge believes that underlying demand remains high, which also applies to the sales region Americas and business area Surgical Workflows, which presented a decrease in order intake in the third quarter.

"Our operating expenses were slightly higher compared with Q3 2018, mainly due to remediation measures and EU MDR preparations, but we can also see that operating expenses are reducing sequentially compared with the preceding quarter, which is a sign that our restructuring measures are starting to show results".

During the third quarter, Getinge launched the operating table Maquet Lyra that meets growing demand in the value segment. The productivity and manufacturing volumes increased in the quarter and contributes to strenghtened margins. Improvements in logistics and inventories are also helping to enhance customer service and reduce costs.

July - September 2019 in brief

Telephone conference

A conference call will be held on October 18, 2019, at 10:00-11:00 CEST hosted by Mattias Perjos, President & CEO, and Lars Sandström, CFO. Please see dial in details below to join the conference:

SE: +46 8 519 993 83       

UK: +44 33 33 009 261     

US: +1 833 823 05 89

During the telephone conference a presentation will be held. To access the presentation through webcast, please use this link: https://tv.streamfabriken.com/getinge-q3-2019 

Alternatively, use the following link to download the presentation: https://www.getinge.com/int/about-us/investors/reports-presentations.

Agenda

09:45    Call in to the conference

10:00    Presentation

10:30    Q&A

11:00    End of conference

Recording available for 3 years

A recorded version can be accessed for 3 years via https://tv.streamfabriken.com/getinge-q3-2019 

Media contact:

Lars Mattson, Head of Investor Relations
Tel: +46(0)10-335-0043
Email: [email protected]

Jeanette Hedén Carlsson, EVP Communication & Academy
Tel: +46(0)10-335-1003
Email: [email protected]

This information is such that Getinge AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, on October 18, 2019, at 08:00 a.m. CEST.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/getinge/r/getinge-q3-2019-result--continued-growth-and-improved-margins,c2935473

The following files are available for download:

https://mb.cision.com/Main/942/2935473/1125466.pdf

Release

https://mb.cision.com/Public/942/2935473/85f176f335b86ee6.pdf

Getinge Interim Report January-September 2019

https://news.cision.com/getinge/i/getinge-maquet-lyra,c2701914

Getinge Maquet Lyra

https://news.cision.com/getinge/i/getinge---mattias-perjos,c2701915

Getinge - Mattias Perjos

SOURCE Getinge


These press releases may also interest you

at 02:25
SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders is pleased to announce a new partnership with Al Shirawi Healthcare solutions, a leading distributor of medical technologies...

at 02:20
BioInvent International (STO:BINV)"During the first quarter of the year, we continued making excellent progress with our clinical pipeline targeting TNFR2 and FcyRIIB, building on the momentum we generated during a very successful 2023. Looking...

at 01:00
PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. ? ?  Q1 2024? Q1 2023? % change? ?m? ?m? ActualCER1Growth...

23 avr 2024
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into...

23 avr 2024
Cybervation, an award-winning global technology and healthcare solutions company, proudly announces that its CEO, Purba Majumder, has been distinguished as one of the 2024 100 Women to KNOW Across America. This award from KNOW Women recognizes...

23 avr 2024
The report titled "Glycated Albumin Assay Market by Product (Animal Glycated Albumin Assay, Human Glycated Albumin Assay), Application (Prediabetes, Type 1 Diabetes, Type 2 Diabetes), End User - Global Forecast 2024-2030" is now available on...



News published on and distributed by: